Drug Discovery & Development

Nucleoside Polymerase Inhibitor Program

IDX184 is Idenix’s unpartnered lead product candidate for the treatment of Hepatitis C virus (HCV). It is a once-daily, oral HCV nucleotide polymerase inhibitor based on Idenix’s proprietary liver-targeting technology. This technology enables the formation of high levels of nucleoside triphosphate, the active form of the drug, in the liver to potentially maximize drug efficacy and limit systemic side effects with low, once-daily dosing.

IDX184 has exhibited a high barrier to resistance and broad genotypic coverage in in vitro studies, has demonstrated potent antiviral activity, and was generally safe and well tolerated in a Phase IIa 14-day study. This clinical trial evaluated IDX184 in combination with pegylated interferon (PegIFN) and ribavirin (RBV) in treatment-naïve HCV genotype 1-infected patients.

In July 2011, the Company initiated enrollment of treatment-naïve genotype 1 HCV-infected patients into a randomized, double-blind, parallel group phase IIb clinical trial of IDX184. The study features two treatment arms, either 50 mg or 100 mg of IDX184 administered once-daily for 12 weeks, each arm in combination with pegylated interferon and ribavirin (PegIFN/RBV). Study objectives include safety and tolerability, and antiviral activity endpoints.

The first 31 patients have completed 28 days of treatment, and the interim data have shown favorable safety and antiviral activity.

View our latest publications and presentations on IDX184

NS5A Inhibitor Program

In January 2012, the Company initiated a phase I clinical trial of the NS5A inhibitor, IDX719. This first part of the study will evaluate safety, pharmacokinetics and food effect of IDX719 in 48 healthy volunteers. A subsequent part of the study will evaluate three days of IDX719 treatment in treatment-naïve genotype 1 HCV-infected patients and is expected to begin in the second quarter of 2012. Preclinical studies have shown that IDX719 has potent, pan-genotypic activity in vitro with the potential for once-daily dosing.

View our latest publications and presentations on our NS5A Program

Nucleoside/tide Program

Idenix has selected two additional nucleotide inhibitors, IDX19368 and IDX19370, as potential clinical candidates. The Company anticipates Investigational New Drug (IND) filings in mid-2012.

View our latest publications and presentations on our Nucleoside/tide Program

 

 Use of Non-Human Primates (NHPs) in the Discovery and Development of Medicines
“Idenix Pharmaceuticals, Inc. has voluntarily decided to continue its practice of not using great apes in research.”